A case series of pediatric primary central nervous system lymphoma: Favorable outcome without cranial irradiation

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 880-885

  Abla, Oussama ^a   Sandlund, John T ^b   Sung, Lillian ^a   Brock, Penelope ^c   Corbett, Rob ^d   Kirov, Ivan ^e   Griffin, Timothy C ^f   Blaser, Susan ^a   Weitzman, Sheila ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d South Island Child Cancer Service   (New Zealand)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^f Cook Children's Medical Center ^*  (United States)

Author keywords

Children; Lymphoma; Primary CNS

Indexed keywords

CARBOPLATIN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE STUDY; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MALE; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; FEMALE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; RETROSPECTIVE STUDIES;

EID: 33750466569     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20736     Document Type: Review

References (29)

1. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: Factors influencing survival in 111 patients. Cancer 2004;vol 100:2627-2636.
2. Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of epstein-barr virus-associated primary central nervous system lymphoma. Cancer Res 2003;63:965-971.
3. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and longterm follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60.
4. Blay JY, Ongolo-Zogo P, Sebban C, et al. Primary Cerebral lymphomas: Unsolved issues regarding first line treatment, follow-up, late neurological toxicity and treatment of relapses. Ann Oncol 2000;11:39-44.
5. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy. Blood 2000;95:2770-2775.
6. Said JA, Waters BG, Cousens P, et al. Neuropsychological sequelae of central nervous system prophylaxis in survivors of childhood acute lymphoblastic leukemia. J Consult Clin Psychol 1989;57:251-256.
7. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized FAB LMB 96 international study in children and adolescents with advanced bone marrow and/or CNS B-NHL: Patients with L3 leukemia/CNS- have an excellent prognosis. Proc. ASCO 2003;22:796.
8. Cohen IJ, Vogel R, Matz S, et al. Successful non-neurotoxic therapy (without radiation) of a multifocal primary brain lymphoma with a methotrexate, vincristine and BCNU protocol (DEMOB). Cancer 1986;57:6-11.
9. Kirov I, Shen V, Lones MA. Primary central nervous system B-cell lymphoma in childhood. J Pediatr Hematol Oncol 2003;vol. 25: S11; Abstract #46.
10. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. J Clin Oncol 2000;18:3144-3150.
11. Watanabe T, Katayama Y, Yoshino A, et al. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neurooncol 2003;63:87-95.
12. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single agent high-dose methotrexate for primary Central nervous System Lymphoma. Ann Neurol 2002;51:247-252.
13. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 2003;21:1044-1049.
14. Guha-Thakurta N, Damek D, Pollack C, et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients. J Neurooncol 1999;43:259-268.
15. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-4648.
16. Slevin ML, Piall EM, Aherne GW, et al. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol 1982;10:157-168.
17. Ferreri AJ, reni M, Pasini f, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-1520.
18. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trials. Ann Oncol 2000;11:927-937.
19. Pels H, Schmidt-Wolf I, Glasmacher A, et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495.
20. Pirotte B, Levivier M, Golman S, et al. Glucocorticoid-induced long term remission in primary cerebral lymphoma: Case report and review of the literature. J Neurooncol 1997;32:63-69.
21. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999;43:199-201.
22. Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-178.
23. Khalfallah S, Stamatoullas A, Fruchart C, et al. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996;18:1021-1023.
24. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-749.
25. Cheng T, Forsyth P, Chaudhry A, et al. Lymphoma: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679-685.
26. Kraemer DF, Fortin D, Doolittle ND, et al. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001;48:1033-1041.
27. Bessell EM, Graus F, Lopez-Guillermo A, et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Longterm survival and prognostic factors. Int J radiat Oncol Biol Phys 2004;59:501-508.
28. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519-526.
29. Ferreri AJ, Batchelor T, Zucca E, et al. International Collaborative Group against primary CNS lymphomas. J Clin Oncol 2003;21:1649-1650.